Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jun Teishima

Showing results (141-150 of 240) with videos related to

Pageof 24
Sort By:
International Cancer Conference Journal|October 3, 2022
Two case reports of immune checkpoint therapy on chromophobe renal cell carcinoma with sarcomatoid differentiationTakafumi Fukushima, Jun Teishima, Keisuke Goto, et al.
International Urology and Nephrology|September 26, 2019
Predictors of poor response to first-generation anti-androgens as criteria for alternate treatments for patients with non-metastatic castration-resistant prostate cancerKenichiro Fukuoka, Jun Teishima, Hirotaka Nagamatsu, et al.
Japanese Journal of Clinical Oncology|August 8, 2018
Preoperative risk classification using neutrophil-lymphocyte ratio and hydronephrosis for upper tract urothelial carcinomaYuki Kohada, Tetsutaro Hayashi, Keisuke Goto, et al.
International Journal of Clinical Oncology|February 7, 2025
Longitudinal assessment of bone mineral density in prostate cancer patients: comparing metastatic and non-metastatic regionsTakuto Hara, Hanako Nishimoto, Tomoaki Terakawa, et al.
International Journal of Clinical Oncology|May 19, 2026
Prognostic significance of early tumor shrinkage in metastatic renal cell carcinoma treated with first-line immune checkpoint inhibitor-based combination therapyNaoki Matsuyama, Takuto Hara, Hideto Ueki, et al.
Molecular and Clinical Oncology|June 28, 2021
Erratum: Improved prognosis for elderly patients with metastatic renal cell carcinoma in the era of targeted therapyJun Teishima, Daiki Murata, Shogo Inoue, et al.
Pathology International|September 28, 2022
Clinicopathological significance of the overexpression of MUC1 in upper tract urothelial carcinoma and possible application as a diagnostic markerGo Kobayashi, Tetsutaro Hayashi, Kazuhiro Sentani, et al.
Clinical Genitourinary Cancer|November 21, 2024
Dose Per Body Weight Predicts Incidence and Severity of Apalutamide-Related Skin Rash in Metastatic Castration-Sensitive Prostate CancerKotaro Suzuki, Yusuke Shiraishi, Yasuyoshi Okamura, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|October 1, 2024
Effects of modifying hinotori™ surgical robot system on perioperative outcome of robot-assisted radical prostatectomyJun Teishima, Naoto Wakita, Yukari Bando, et al.
Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology|July 5, 2022
ANXA10 Expression Is Inversely Associated with Tumor Stage, Grade, and TP53 Expression in Upper and Lower Urothelial CarcinomaGo Kobayashi, Tetsutaro Hayashi, Kazuhiro Sentani, et al.
Pageof 24

Showing results (141-150 of 240) with videos related to

Sort By:
Pageof 24
International Cancer Conference Journal|October 3, 2022
Two case reports of immune checkpoint therapy on chromophobe renal cell carcinoma with sarcomatoid differentiationTakafumi Fukushima, Jun Teishima, Keisuke Goto, et al.
International Urology and Nephrology|September 26, 2019
Predictors of poor response to first-generation anti-androgens as criteria for alternate treatments for patients with non-metastatic castration-resistant prostate cancerKenichiro Fukuoka, Jun Teishima, Hirotaka Nagamatsu, et al.
Japanese Journal of Clinical Oncology|August 8, 2018
Preoperative risk classification using neutrophil-lymphocyte ratio and hydronephrosis for upper tract urothelial carcinomaYuki Kohada, Tetsutaro Hayashi, Keisuke Goto, et al.
International Journal of Clinical Oncology|February 7, 2025
Longitudinal assessment of bone mineral density in prostate cancer patients: comparing metastatic and non-metastatic regionsTakuto Hara, Hanako Nishimoto, Tomoaki Terakawa, et al.
International Journal of Clinical Oncology|May 19, 2026
Prognostic significance of early tumor shrinkage in metastatic renal cell carcinoma treated with first-line immune checkpoint inhibitor-based combination therapyNaoki Matsuyama, Takuto Hara, Hideto Ueki, et al.
Molecular and Clinical Oncology|June 28, 2021
Erratum: Improved prognosis for elderly patients with metastatic renal cell carcinoma in the era of targeted therapyJun Teishima, Daiki Murata, Shogo Inoue, et al.
Pathology International|September 28, 2022
Clinicopathological significance of the overexpression of MUC1 in upper tract urothelial carcinoma and possible application as a diagnostic markerGo Kobayashi, Tetsutaro Hayashi, Kazuhiro Sentani, et al.
Clinical Genitourinary Cancer|November 21, 2024
Dose Per Body Weight Predicts Incidence and Severity of Apalutamide-Related Skin Rash in Metastatic Castration-Sensitive Prostate CancerKotaro Suzuki, Yusuke Shiraishi, Yasuyoshi Okamura, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|October 1, 2024
Effects of modifying hinotori™ surgical robot system on perioperative outcome of robot-assisted radical prostatectomyJun Teishima, Naoto Wakita, Yukari Bando, et al.
Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology|July 5, 2022
ANXA10 Expression Is Inversely Associated with Tumor Stage, Grade, and TP53 Expression in Upper and Lower Urothelial CarcinomaGo Kobayashi, Tetsutaro Hayashi, Kazuhiro Sentani, et al.
Pageof 24